- Muscular Dystrophy UK (MDUK) supports high quality research that drives rapid access to emerging therapies for people with muscle-wasting conditions.
- Facioscapulohumeral muscular dystrophy (FSHD) is a rare muscle-wasting disease affecting an estimated 3-5 in every 100,000 people worldwide.
- This partnership will combine Healx’s AI-driven drug discovery expertise with MDUK’s patient insight to identify novel therapeutic options for FSHD.
News
The BioChemGRAPH collaboration brings together key chemical and biochemical datasets, to give researchers deeper insights than ever before.
A collaboration announced today will see the integration of key structural, functional, and biochemical data across both small molecules and macromolecules. This will allow researchers to quickly access relevant information from trusted but disparate datasets, advancing work in fields such as target validation, drug development, drug repurposing and cross-reactivity.
The Aim
Cambridge, United Kingdom – 15 July 2020 - Congenica, a digital health company enabling rapid analysis of complex genomic data, has launched an update for its clinical decision support platform that will provide automated classification, evidence and reporting of recurrent ‘known’ variants that customers observe in their rare disease cases, significantly saving time while maximizing diagnostic yield and laboratory throughput.
Eastern AHSN (Academic Health Science Network) has published its latest impact review (for the period April 2019 to 31 March 2020) highlighting how they turned great ideas into positive health impact last year, told largely in the words of the people they worked with.
San Diego, California and Saffron Walden, UK, 14th July 2020 / Sciad Newswire / Invivoscribe, Inc., an industry pioneer and global leader in the field of precision diagnostics announces the launch of a fully integrated drug development engine. This new engine will combine with its in-house expertise in diagnostics development and worldwide access to patients and clinical testing capabilities to accelerate drug development.
A Spanish SME, in collaboration with a local University, has been developing an advanced drug delivery system which allows to increase the therapeutic efficacy of chemotherapeutics against Non-Small Cell Lung Cancer (NSCLC). The goal of this Eurostars proposal is to obtain a full-characterized antitumoral product ready to be tested in clinical trials. They are looking for a partner to carry out the preclinical regulatory trials.
Now that lockdown measures are beginning to ease and the prospect of meeting up with friends and family in a restaurant or having a drink in a pub has arrived, businesses are planning for what a return to the workplace will look like.
But as lockdown measures gradually begin to ease and we all start to look towards the future, businesses are and have been continually pondering and planning for what a return to the workplace will look like.
We are delighted to announce Illumina Accelerator is accepting applications for its next global funding cycle in the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator is the world’s first business accelerator focused on creating an innovation ecosystem for the genomics industry.
We continue to feel the impact of COVID-19, on a personal, organisational and national level.
For those working in supply chain management, COVID-19 has been the latest in a recent series of disruptive global challenges, including volcanic eruptions, earthquakes and war. Such global challenges undoubtedly lead to supply chain shock.
Unlike some challenges which are contained within regions, states or continents, the pandemic has sent shockwaves across the entire globe. As a result, all international supply chains have felt the effects of COVID-19.